Free tool
Upcoming earnings calendar
See who reports in the next 30, 60 or 90 days, from the ~22,000 stocks we cover — filter by cap, sector, theme or market, then open any ticker for the full analysis.
See who reports in the next 30, 60 or 90 days, from the ~22,000 stocks we cover — filter by cap, sector, theme or market, then open any ticker for the full analysis.
See who reports in the US in the next 90 days, from the ~22,000 stocks we cover — filter by cap, sector, theme or market, then open any ticker for the full analysis.
77 companies reporting in the next 90 days. Clear filters
Data as of Aug 26, 2026 · updates nightly, Mon–Sat
| Ticker | Company | Theme | Market cap (USD) | 1M return | |
|---|---|---|---|---|---|
| Wednesday, Sep 16 · in 20 days · 1 company | |||||
| RZLT | Rezolute, Inc. | Rare disease | $482.42M | +1.42% | |
| Monday, Oct 26 · in 60 days · 1 company | |||||
| 0HNC.L | BioMarin Pharmaceutical Inc. | Rare disease | $9.93B | +0.37% | |
| Tuesday, Oct 27 · in 61 days · 1 company | |||||
| ARQT | Arcutis Biotherapeutics, Inc. | Rare disease | $3.12B | −10.70% | |
| Wednesday, Oct 28 · in 62 days · 1 company | |||||
| RFL | Rafael Holdings, Inc. | ||||
Price chart, technicals, money flow, fundamentals and an AI-written read — one page per stock. Looking for a name that isn't listed? Jump straight to it:
| Rare disease |
| $113.88M |
| −1.75% |
| Thursday, Oct 29 · in 63 days · 4 companies | |||||
| TVTX | Travere Therapeutics, Inc. | Rare disease | $6.06B | +18.23% | |
| AGIO | Agios Pharmaceuticals, Inc. Common Stock | Rare disease | $1.95B | −8.30% | |
| 0HB0.L | Agios Pharmaceuticals, Inc. | Rare disease | $1.19B | +2.11% | |
| FULC | Fulcrum Therapeutics, Inc. | Rare disease | $294.51M | +3.49% | |
| Monday, Nov 2 · in 67 days · 1 company | |||||
| BCRX | BioCryst Pharmaceuticals, Inc. | Rare disease | $2.51B | +2.61% | |
| Tuesday, Nov 3 · in 68 days · 6 companies | |||||
| RYTM | Rhythm Pharmaceuticals, Inc. | Rare disease | $7.78B | +6.80% | |
| LQDA | Liquidia Corporation | Rare disease | $6.31B | −16.50% | |
| RARE | Ultragenyx Pharmaceutical Inc. | Rare disease | $2.61B | −1.60% | |
| STOK | Stoke Therapeutics, Inc. | Rare disease | $2.16B | +14.16% | |
| 0LIF.L | Ultragenyx Pharmaceutical Inc. | Rare disease | $1.40B | +3.33% | |
| CPIX | Cumberland Pharmaceuticals Inc. | Rare disease | $130.35M | +59.59% | |
| Wednesday, Nov 4 · in 69 days · 10 companies | |||||
| MIRM | Mirum Pharmaceuticals, Inc. | Rare disease | $5.98B | −14.12% | |
| ADMA | ADMA Biologics, Inc. | Rare disease | $2.14B | +14.62% | |
| 0L35.L | Sarepta Therapeutics, Inc. | Rare disease | $1.69B | +3.95% | |
| TYRA | Tyra Biosciences, Inc. | Rare disease | $1.59B | −14.07% | |
| ZVRA | Zevra Therapeutics, Inc. | Rare disease | $714.98M | +24.00% | |
| AQST | Aquestive Therapeutics, Inc. | Rare disease | $602.46M | +36.19% | |
| UPB | Upstream Bio, Inc. | Rare disease | $393.26M | +12.19% | |
| GOSS | Gossamer Bio, Inc. | Rare disease | $99.97M | +2.76% | |
| SCYX | SCYNEXIS, Inc. | Rare disease | $51.64M | +45.38% | |
| MCRB | Seres Therapeutics, Inc. | Rare disease | $46.81M | +3.09% | |
| Thursday, Nov 5 · in 70 days · 17 companies | |||||
| EWTX | Edgewise Therapeutics, Inc. | Rare disease | $4.80B | +6.27% | |
| AMLX | Amylyx Pharmaceuticals, Inc. | Rare disease | $4.17B | +92.20% | |
| VRDN | Viridian Therapeutics, Inc. | Rare disease | $2.74B | +22.74% | |
| VERA | Vera Therapeutics, Inc. | Rare disease | $2.54B | +0.28% | |
| MAZE | Maze Therapeutics, Inc. | Rare disease | $1.69B | +6.03% | |
| TRAX | First Tracks Biotherapeutics, Inc. | Rare disease | $1.61B | +7.33% | |
| XERS | Xeris Biopharma Holdings, Inc. | Rare disease | $1.59B | +6.46% | |
| TECX | Tectonic Therapeutic, Inc. | Rare disease | $737.21M | +23.20% | |
| GYRE | Gyre Therapeutics, Inc. | Rare disease | $682.86M | +8.97% | |
| LRMR | Larimar Therapeutics, Inc. | Rare disease | $432.15M | +8.62% | |
| XFOR | X4 Pharmaceuticals, Inc. | Rare disease | $412.45M | +5.58% | |
| TRDA | Entrada Therapeutics, Inc. | Rare disease | $296.70M | +25.33% | |
| SION | Sionna Therapeutics, Inc. | Rare disease | $282.58M | −86.23% | |
| IVVD | Invivyd, Inc. | Rare disease | $277.81M | +53.89% | |
| SIGA | SIGA Technologies, Inc. | Rare disease | $211.24M | −1.94% | |
| 0H8T.L | Aclaris Therapeutics, Inc. | Rare disease | $122.82M | +6.50% | |
| ATYR | aTyr Pharma, Inc. | Rare disease | $55.91M | +16.33% | |
| Friday, Nov 6 · in 71 days · 1 company | |||||
| ANIP | ANI Pharmaceuticals, Inc. | Rare disease | $1.74B | −3.47% | |
| Monday, Nov 9 · in 74 days · 3 companies | |||||
| SEPN | Septerna, Inc. | Rare disease | $1.93B | +23.32% | |
| FBRX | Forte Biosciences, Inc. | Rare disease | $1.63B | +0.61% | |
| ANNX | Annexon, Inc. | Rare disease | $976.33M | +0.39% | |
| Tuesday, Nov 10 · in 75 days · 4 companies | |||||
| MLYS | Mineralys Therapeutics, Inc. | Rare disease | $2.32B | −3.20% | |
| SPRY | ARS Pharmaceuticals, Inc. | Rare disease | $568.84M | −0.69% | |
| INO | Inovio Pharmaceuticals, Inc. | Rare disease | $129.25M | +32.99% | |
| JSPR | Jasper Therapeutics, Inc. | Rare disease | $23.96M | +3.78% | |
| Wednesday, Nov 11 · in 76 days · 4 companies | |||||
| ORKA | Oruka Therapeutics, Inc. | Rare disease | $6.74B | +12.88% | |
| SVRA | Savara Inc. | Rare disease | $1.15B | +3.13% | |
| AVIR | Atea Pharmaceuticals, Inc. | Rare disease | $441.93M | +12.66% | |
| ARMP | Armata Pharmaceuticals, Inc. | Rare disease | $206.73M | +7.96% | |
| Thursday, Nov 12 · in 77 days · 17 companies | |||||
| MANE | Veradermics, Incorporated | Rare disease | $4.11B | −8.14% | |
| NKTR | Nektar Therapeutics | Rare disease | $2.52B | +5.06% | |
| ZBIO | Zenas BioPharma, Inc. | Rare disease | $2.20B | +2.89% | |
| ETON | Eton Pharmaceuticals, Inc. | Rare disease | $1.80B | +49.02% | |
| OMER | Omeros Corporation | Rare disease | $1.40B | +70.02% | |
| JBIO | Jade Biosciences, Inc. | Rare disease | $1.39B | +9.47% | |
| STTK | Shattuck Labs, Inc. | Rare disease | $792.87M | +14.49% | |
| ZURA | Zura Bio Limited | Rare disease | $605.64M | +17.47% | |
| 0KBU.L | Omeros Corporation | Rare disease | $575.28M | −0.10% | |
| TTRX | Turn Therapeutics Inc. | Rare disease | $295.48M | +25.06% | |
| PLX | Protalix BioTherapeutics, Inc. | Rare disease | $193.37M | +0.42% | |
| AARD | Aardvark Therapeutics, Inc. | Rare disease | $158.67M | +8.37% | |
| PTHS | Pelthos Therapeutics Inc. | Rare disease | $104.13M | −1.41% | |
| SPRO | Spero Therapeutics, Inc. | Rare disease | $70.76M | +4.24% | |
| QNCX | Quince Therapeutics, Inc. | Rare disease | $34.05M | +73.28% | |
| TVRD | Tvardi Therapeutics, Inc. | Rare disease | $23.74M | −28.35% | |
| JAGX | Jaguar Health, Inc. | Rare disease | $4.78M | −7.51% | |
| Friday, Nov 13 · in 78 days · 2 companies | |||||
| IKT | Inhibikase Therapeutics, Inc. | Rare disease | $348.84M | +6.38% | |
| ELDN | Eledon Pharmaceuticals, Inc. | Rare disease | $281.98M | −2.80% | |
| Monday, Nov 16 · in 81 days · 4 companies | |||||
| COAG | Hemab Therapeutics Holdings, Inc. | Rare disease | $2.32B | −1.47% | |
| AVLN | Avalyn Pharma Inc. | Rare disease | $1.69B | +38.31% | |
| CRMD | CorMedix Inc. | Rare disease | $667.20M | +12.63% | |
| ENTA | Enanta Pharmaceuticals, Inc. | Rare disease | $410.67M | +10.60% | |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India). Reporting dates are public estimates and can shift.